Application experience of enzalumide in mCRPC patients with cardiopulmonary disease
10.3760/cma.j.cn112330-20210908-00012
- VernacularTitle:恩扎卢胺在伴心肺疾病mCRPC患者中的应用经验
- Author:
Caoyang HU
1
;
Jinming TIAN
;
Yongquan CHEN
Author Information
1. 山西医科大学第一医院泌尿外科，太原 030000
- Keywords:
Metastatic castration-resistant prostate cancer;
Androgen deprivation therapy;
Enzalutamide
- From:
Chinese Journal of Urology
2021;42(Z2):40-42
- CountryChina
- Language:Chinese
-
Abstract:
Metastatic castration-resistant prostate cancer (mCRPC) is the inevitable form of most prostate cancers after endocrine therapy, and conventional drugs are not effective at this time.In this case, an elderly mCRPC patient with cardiopulmonary diseases admitted to the First Hospital of Shanxi Medical University in August 2020 was selected. After the failure of traditional endocrine therapy, enzalumide+ ADT regimen was adopted, and the patient's blood PSA was significantly reduced without cardiopulmonary adverse events.
